PAEAN Biotechnology
CompanySouth Korea
PAEAN Biotechnology develops one asset, in phase 2 (PN-101 in dermatomyositis). Mostly other acting on oxidative phosphorylation and Mitochondrial biogenesis (PGC-1α); based in South Korea.
- Assets
- 1
- Furthest
- Phase 2
- Trials
- 2
- Signals
- 0
Pipeline
1Allogeneic mesenchymal stem cell-derived mitochondria transfer
Phase 2OtherOxidative phosphorylationMitochondrial biogenesis (PGC-1α)dermatomyositispolymyositis
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms2
- Trials2
- Similar companies6
Updated 7 Oct 2026 · 5 sources